Notable Labs (NASDAQ:NTBL) Price Target Cut to $5.00 by Analysts at Chardan Capital

Notable Labs (NASDAQ:NTBL) had its target price decreased by Chardan Capital from $7.00 to $5.00 in a research report report published on Thursday morning, Benzinga reports. Chardan Capital currently has a buy rating on the stock.

Separately, JMP Securities reiterated a market outperform rating and set a $9.00 target price on shares of Notable Labs in a research report on Monday, April 15th.

Notable Labs Stock Performance

NASDAQ NTBL opened at $1.02 on Thursday. The stock has a 50-day moving average of $1.33 and a 200 day moving average of $1.84. The company has a quick ratio of 5.65, a current ratio of 5.65 and a debt-to-equity ratio of 0.02. Notable Labs has a twelve month low of $0.83 and a twelve month high of $11.20.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Notable Labs stock. Industry Ventures L.L.C. bought a new stake in shares of Notable Labs, Ltd. (NASDAQ:NTBL) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 204,424 shares of the company’s stock, valued at approximately $386,000. Notable Labs comprises about 0.6% of Industry Ventures L.L.C.’s portfolio, making the stock its 6th biggest holding. Industry Ventures L.L.C. owned approximately 9.21% of Notable Labs as of its most recent SEC filing. 70.48% of the stock is owned by institutional investors.

Notable Labs Company Profile

Notable Labs, Ltd., a clinical-stage platform therapeutics company, engages in developing predictive precision medicines for patients with cancer. The company, through its proprietary Predictive Precision Medicines Platform (PPMP), bio-simulates a cancer treatment and predicts, whether or not the patient is likely to respond to that specific therapeutic.